Apollomics Inc Cl A (APLM)

$9.29 +2.46 (36.02%)
Market Cap 7.54M
Revenue (ttm) 1.49M
Net Income (ttm) -53.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,614.77%
Debt to Equity Ratio 0.00
Volume 232,300
Avg Vol 48,062
Day's Range N/A - N/A
Shares Out 1.10M
Stochastic %K 89%
Beta 0.90
Analysts Strong Buy
Price Target $6.50

Company Profile

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; APL-102, an oral active, small molecule multip...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 209 4055
Fax: 650 288 1674
Address:
989 East Hillsdale Blvd., Suite 220, Foster City, United States
StockScanners
StockScanners Sep. 16 at 3:51 AM
$APLM keep watch if this holds above 8.20
0 · Reply
GJ_Rockabilt
GJ_Rockabilt Sep. 16 at 3:32 AM
$APLM What's the Shelf Life on Dead Duck?
0 · Reply
PrimeTimeHour
PrimeTimeHour Sep. 16 at 1:14 AM
Top watch ticker for Tomorrow: CNFR CNFR strong close after hours, and many are just finding this one. Known for big multi days runs. If you want to bank this week, keeping CNFR and being early on it will pay massive!! Great day on: $ORIS $APLM $SLNH $BGL
0 · Reply
CAPITALWHISPERER
CAPITALWHISPERER Sep. 15 at 6:47 PM
$OPI $1.20 next leg. $3.5 BILLION assets omg new $APLM and $CHEK
1 · Reply
topstockalerts
topstockalerts Sep. 15 at 3:56 PM
Top Gainers PT2 $RCEL $GLUE $LVLU $APLM $WOLF
0 · Reply
dbr_island
dbr_island Sep. 15 at 3:52 PM
$IHT BOOM $INVZ adding and adding and adding 🚢📦📦🚨 Shouldn’t be under $2 or even $3 or $4 WATCH AND LEARN $NAOV $APLM $ATCH let’s get it
0 · Reply
Wakejobe
Wakejobe Sep. 15 at 3:29 PM
$APLM Danger!!! Exit pump! Do not be the bag
1 · Reply
Jompa89
Jompa89 Sep. 15 at 3:20 PM
$APLM lets go!!! 🔥
0 · Reply
STOCKSGambino
STOCKSGambino Sep. 15 at 3:12 PM
$APLM https://x.com/StocksGambino/status/1967606936855347622
0 · Reply
BigSqueezeComing
BigSqueezeComing Sep. 15 at 2:50 PM
$APLM Hot stocks.
0 · Reply
Latest News on APLM
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

Apr 3, 2025, 4:05 PM EDT - 5 months ago

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

Mar 31, 2025, 8:00 AM EDT - 6 months ago

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Dec 20, 2024, 8:00 AM EST - 9 months ago

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Dec 10, 2024, 4:05 PM EST - 9 months ago

Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Aug 14, 2024, 6:00 AM EDT - 1 year ago

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Jul 16, 2024, 4:47 PM EDT - 1 year ago

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

Jul 3, 2024, 8:00 AM EDT - 1 year ago

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Apr 25, 2024, 8:30 AM EDT - 1 year ago

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Apr 10, 2024, 7:00 AM EDT - 1 year ago

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 3:57 PM EDT - 1 year ago

Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Mar 28, 2024, 7:00 AM EDT - 1 year ago

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

Mar 4, 2024, 7:00 AM EST - 1 year ago

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 7, 2024, 7:00 AM EST - 1 year ago

Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Jan 19, 2024, 4:15 PM EST - 1 year ago

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology Conference

Jan 17, 2024, 4:30 PM EST - 1 year ago

Apollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology Conference

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Jan 3, 2024, 7:00 AM EST - 1 year ago

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Apollomics to Present at the 2024 Biotech Showcase

Jan 2, 2024, 4:30 PM EST - 1 year ago

Apollomics to Present at the 2024 Biotech Showcase

Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Nov 29, 2023, 7:30 AM EST - 1 year ago

Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)

Nov 28, 2023, 7:00 AM EST - 1 year ago

Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)

Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer

Nov 16, 2023, 8:30 AM EST - 1 year ago

Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer

Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation

Oct 31, 2023, 8:30 AM EDT - 2 years ago

Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation

Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion

Oct 26, 2023, 8:50 AM EDT - 2 years ago

Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion

Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%

Oct 23, 2023, 8:30 AM EDT - 2 years ago

Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%

Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023

Oct 16, 2023, 6:55 PM EDT - 2 years ago

Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023

Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

Sep 28, 2023, 4:17 PM EDT - 2 years ago

Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Apollomics: A Taiwanese-Origin Company With Late Stage Pipeline

Aug 29, 2023, 6:21 AM EDT - 2 years ago

Apollomics: A Taiwanese-Origin Company With Late Stage Pipeline

Top 5 Health Care Stocks That Are Preparing To Pump In Q2 - AngioDynamics (NASDAQ:ANGO), Apollomics (NASDAQ:APLM)

Apr 26, 2023, 7:45 AM EDT - 2 years ago

Top 5 Health Care Stocks That Are Preparing To Pump In Q2 - AngioDynamics (NASDAQ:ANGO), Apollomics (NASDAQ:APLM)

ANGO

Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R.

Apr 11, 2023, 8:30 AM EDT - 2 years ago

Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R.

Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination

Jan 13, 2023, 4:13 PM EST - 2 years ago

Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination

Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination

Oct 7, 2022, 4:05 PM EDT - 3 years ago

Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination

StockScanners
StockScanners Sep. 16 at 3:51 AM
$APLM keep watch if this holds above 8.20
0 · Reply
GJ_Rockabilt
GJ_Rockabilt Sep. 16 at 3:32 AM
$APLM What's the Shelf Life on Dead Duck?
0 · Reply
PrimeTimeHour
PrimeTimeHour Sep. 16 at 1:14 AM
Top watch ticker for Tomorrow: CNFR CNFR strong close after hours, and many are just finding this one. Known for big multi days runs. If you want to bank this week, keeping CNFR and being early on it will pay massive!! Great day on: $ORIS $APLM $SLNH $BGL
0 · Reply
CAPITALWHISPERER
CAPITALWHISPERER Sep. 15 at 6:47 PM
$OPI $1.20 next leg. $3.5 BILLION assets omg new $APLM and $CHEK
1 · Reply
topstockalerts
topstockalerts Sep. 15 at 3:56 PM
Top Gainers PT2 $RCEL $GLUE $LVLU $APLM $WOLF
0 · Reply
dbr_island
dbr_island Sep. 15 at 3:52 PM
$IHT BOOM $INVZ adding and adding and adding 🚢📦📦🚨 Shouldn’t be under $2 or even $3 or $4 WATCH AND LEARN $NAOV $APLM $ATCH let’s get it
0 · Reply
Wakejobe
Wakejobe Sep. 15 at 3:29 PM
$APLM Danger!!! Exit pump! Do not be the bag
1 · Reply
Jompa89
Jompa89 Sep. 15 at 3:20 PM
$APLM lets go!!! 🔥
0 · Reply
STOCKSGambino
STOCKSGambino Sep. 15 at 3:12 PM
$APLM https://x.com/StocksGambino/status/1967606936855347622
0 · Reply
BigSqueezeComing
BigSqueezeComing Sep. 15 at 2:50 PM
$APLM Hot stocks.
0 · Reply
MRWILL_
MRWILL_ Sep. 15 at 2:46 PM
$APLM
0 · Reply
makedatbread88
makedatbread88 Sep. 15 at 2:46 PM
$APLM another 100% gainer… NEXT is $LVLU ***Follow me for more winning calls!***
0 · Reply
ucantcatchmegaythots
ucantcatchmegaythots Sep. 15 at 2:43 PM
$APLM can anyone explain this to me?.. they are dissolving the business and ending the company (as per filing) but the price is going up?... we need a smart person in here... am i buying a company going out of business or is that a crazy idea?
0 · Reply
wetakeWs
wetakeWs Sep. 11 at 8:17 PM
What is happening to ticker ADXN ?! Looks like they are pumping ADXN for 300% today, its starting to breakout! Shorts overextended and now bulls can have them trapped at the bottom. ADXN Could pull a huge multi day run - only 600k float! Everyone moving to ADXN ?! $APLM $KAPA $ZONE $NUKK movers
0 · Reply
GJ_Rockabilt
GJ_Rockabilt Sep. 9 at 2:53 AM
Monday Night 09/08/2025 GOOGLE on $APLM: " As of September 2025, Apollomics is in the process of being wound up and is not actively trading. While this is a form of dissolution that indicates major financial distress, it is not the same as a typical bankruptcy filing." " In an extraordinary general meeting on September 4, 2025, Apollomics shareholders voted to approve the winding up of the company. This was done at the recommendation of the company's board of directors." Monday Night stat from YAHOO FINANCE: "Volume 28.89K". WTF? I didn't Buy it. Why would you?
0 · Reply
AlwaysStayGreen
AlwaysStayGreen Sep. 5 at 3:25 AM
Ticker VEEE is setting up to be a monster runner, we had a nice a preview of it yesterday when it ran to $3+. This time with more people finding this gem, we could even see higher. 0 shares to borrow now as well. Great setup! I am also watching $VMAR $SOGP $APLM $PAVS Nice day overall on these.
0 · Reply
Stock_Catcher
Stock_Catcher Sep. 5 at 1:51 AM
Fortune Friday Watchlist Pt. 6 $DLTH $BSLK $HWH $XFOR $APLM Let's Find Some Big Ones 🎯
0 · Reply
StockScanners
StockScanners Sep. 5 at 12:49 AM
$APLM keep watch if this holds above 5.00
0 · Reply
makedatbread88
makedatbread88 Sep. 4 at 8:32 PM
$APLM another winning call ***Follow me for more winning calls!***
0 · Reply
GJ_Rockabilt
GJ_Rockabilt Sep. 4 at 4:43 PM
$APLM Sick joke.
0 · Reply
makedatbread88
makedatbread88 Sep. 4 at 2:04 PM
$APLM wow another winning call who else is giving these out nonstop?! ***Follow me for more winning calls!***
0 · Reply
ucantcatchmegaythots
ucantcatchmegaythots Sep. 4 at 1:59 PM
$APLM can someone explain the pump to me, they said they are going out of business , fired all the employees.... is this just the last try to cash out?... they cancelled all trials and all work
0 · Reply